In 2000, the Centers for Disease Control and Prevention
announced the elimination of measles in the United States.
Twenty-five years later, however, the US is experiencing a
resurgence of the disease. In 2025, there were over 2,200 confirmed
measles cases. The number of cases may rise further in 2026, with
733 confirmed cases in January alone.
Over the past decade, anti-vaccine social media campaigns and
growing mistrust of public health institutions have made more parents
delay or refuse the measles-mumps-rubella (MMR) vaccine for their
children. Seemingly well-protected cities now contain clusters of
communities where vaccination rates have quietly fallen below the
level needed for herd immunity.
The vaccine uses a weakened form of the virus to present viral
proteins to the body. When the immune system encounters the
proteins, it develops counteracting antibodies that can fight off the
apparent infection. However, while primary measles infection carries a
measurable rate of hospitalization and mortality, the vaccine generates an equally effective antibody response without the risk of potentially life-threatening complications associated with natural measles infections. Those ineligible to receive the vaccine, such as infants and those with
immune deficiencies, face severe risks when vaccination rates drop
below the ninety-percent protective threshold, as in South Carolina and
Texas, two states with recent measles outbreaks.
The recent resurgence of measles serves as a sobering warning
that vaccine-preventable diseases can make a similar comeback
if coverage dips below critical thresholds. To protect infants,
immunocompromised individuals, and entire communities,
immunization must be reinvigorated through targeted incentives and
measures to counter misinformation.